Takeda Pharmaceutical envisions a potentially significant market in polycythemia vera (PV) for rusfertide, which it is developing together with Protagonist Therapeutics, after reporting positive Phase III data for the drug. Rusfertide particularly stands to benefit from the more than three-quarters of patients with PV who have uncontrolled hematocrit levels.
Takeda/Protagonist’s Rusfertide Could Be A Main Character In PV After Phase III Data
The companies announced positive data from the VERIFY study among patients with PV, showing lower proportions of patients requiring phlebotomy.
More from Anticancer
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.